Halo Pharmaceutical

What Halo Pharmaceutical does

Halo Pharmaceutical is a contract development and manufacturing organization (CDMO) headquartered in Whippany, New Jersey, with primary manufacturing operations at a large-scale facility in Mirabel, Quebec, Canada. Founded in 2002 and historically part of the Noramco Group under SK Capital Partners ownership, the company emerged as a standalone CDMO in May 2026 following SK Capital's sale of Noramco to Siegfried. Halo Pharma provides development, manufacturing, and regulatory support services for solid oral dose, semi-solid, oral liquid, and sterile injectable pharmaceutical products, serving generic and branded pharmaceutical companies with a portfolio that includes 400+ commercial SKUs, 120 active development projects, and more than 90 ANDA/NDA filings to date.

The company's technical platform spans formulation development, analytical method development, validation, tech transfer, commercial manufacturing, and packaging across multiple dosage forms. The Mirabel site holds cGMP registrations with FDA, Health Canada, EMA, ANVISA, and MHRA, and operates under DEA registration for Schedule II-V controlled substances — a regulatory footprint that is uncommon among mid-tier CDMOs. The company has been actively expanding its technological capability, including a $30M+ investment in sterile injectable manufacturing anchored by a new Groninger ready-to-use vial filling line, and the addition of Gerteis dry granulation equipment for solid dose work.

Halo Pharma's business model is project-based contract services revenue: customers pay for development milestones, tech transfer, validation, and commercial manufacturing volumes under multi-year supply agreements. The customer base spans 85+ companies, including Top 10 pharmaceutical and generics players, with a strategic anchor relationship with Apotex covering sterile injectable capacity. Revenue is not publicly disclosed, but operational scale (Mirabel alone employs 200+ staff, with corporate headcount in the 101-250 range) and capital intensity are consistent with a mid-tier diversified CDMO serving both branded and generic pharmaceutical innovators.

Name

Halo Pharmaceutical

Legal name

Halo Pharma, Inc.

Website

https://halopharma.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

101–250 employees

Short description

Halo Pharmaceutical is a US-headquartered, Canada-manufactured contract development and manufacturing organization (CDMO) serving 85+ generic and branded pharmaceutical clients with solid dose, semi-solid, oral liquid, and sterile injectable products across 400+ commercial SKUs.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Pharmaceutical contract manufacturing
• Drug product development
• Contract development organization
• Sterile injectable manufacturing
• Pharmaceutical formulation services

Headquarters

HQ city

Whippany

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Contract Development and Manufacturing Services: Halo Pharma generates revenue through contract development and manufacturing services for pharmaceutical companies. Services include formulation development, analytical method development, clinical trial material manufacturing, commercial manufacturing, and tech transfer services. Revenue is generated through project-based contracts with pharmaceutical innovators, generics, and OTC companies for development and manufacturing services across solid dose, semi-solid, oral liquid, and sterile formats.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Halo Pharma is a contract development and manufacturing organization (CDMO) that provides outsourced formulation development, analytical testing, clinical trial material manufacturing, and commercial-scale production of small molecule drug products. The company serves pharmaceutical innovators, generics manufacturers, and OTC product owners across solid dose, semi-solid, oral liquid, and (in 2026) sterile injectable dosage forms from two North American cGMP facilities in Whippany, NJ and Mirabel, Quebec.

Product overview

Halo Pharma is a contract development and manufacturing organization (CDMO) providing end-to-end pharmaceutical development and manufacturing services. The company operates two North American facilities in Whippany, NJ and Mirabel, Quebec, Canada. Core service modules include Development Services, Analytical Services, Clinical Manufacturing (CTM), Commercial Manufacturing, and Quality Services. These services support manufacturing across multiple dosage forms: Solid Dosage Forms (tablets, capsules, powders), Semi-Solid Dosage Forms (creams, ointments, gels), Oral Liquid Dosage Forms (solutions, suspensions, syrups), and Sterile Injectable Dosage Forms (vials, prefilled syringes, cartridges). The company is expanding into sterile manufacturing in 2026 with a $30+ million investment. An Accelerated Tech Transfer Program offers fixed-price engagements for GMP manufacturing in 16-20 weeks.

Differentiator

Problem solved

Functional benefit

Products and services

• Development Services End-to-end formulation and process development services from early development through commercial scale-up, including excipient/API compatibility studies, pre-formulation work, and proof-of-concept prototypes designed with a Quality by Design (QbD) focus for pharmaceutical innovators, generics, and OTC companies.
• Analytical Services Comprehensive analytical testing services including drug substance, drug product, and excipient testing, analytical method development and validation, QC release testing, and stability storage from -20C to 40C/75% RH for pharmaceutical customers.
• Clinical Manufacturing (CTM) cGMP clinical trial material manufacturing from 1 kg/liter to 50 kg/liter with brite stock packaging in bottles and blisters; supported 100+ clinical programs in the last 10 years for pharmaceutical innovators and small biotechs.
• Commercial Manufacturing Over 40 years of commercial pharmaceutical manufacturing experience producing 400+ commercial SKUs across 100 product families annually, including integrated packaging, order fulfillment, distribution, and demand management services for pharmaceutical innovators and generics companies.
• Quality Services Quality assurance and compliance services including rigorous supplier qualification, comprehensive analytical testing, cGMP-compliant processes with real-time monitoring, and continuous improvement culture supporting pharmaceutical customer regulatory requirements.
• Solid Dosage Form Manufacturing Manufacturing of tablets, capsules, powders, and granules with immediate and modified release capabilities, including wet high-shear/fluid bed granulation, dry granulation/compaction, and coating. Batch sizes from 0.5 to 1,000 kg. DEA Schedule II-V and OEB 3 capable.
• Semi-Solid Dosage Form Manufacturing Non-sterile creams, ointments, gels, lotions, and suppositories manufactured using vacuum deration and high-viscous polymer handling. Batch sizes from 3 to 1,000 kg. Located at the Mirabel, Quebec facility with 30+ years of experience.
• Oral Liquid Dosage Form Manufacturing Solutions, suspensions, and syrups manufactured using advanced mixing and homogenization with volume range from 10 to 4,400 liters, filled in plastic and glass bottles. DEA Schedule II-V capable, including pediatric specialties with taste-masking delivery systems.
• Sterile Injectable Manufacturing

Quantifiable outcome

• 120 active product development projects supported
• +5 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• ApotexcoreStrategic or Co-development Partner · 14 April 2026Apotex secured strategic sterile filling partnership with Halo Pharmaceuticals through an investment providing access to significant sterile injectable filling capacity at Halo's Whippany, New Jersey facility. The partnership supports Apotex's U.S.-based manufacturing strategy and sterile injectables network. The arrangement enables Apotex to access near-term sterile filling capacity as an alternative to greenfield development, providing operational flexibility. Apotex brings sterile processing experience, regulatory readiness expertise, and commercialization capabilities while securing access to vial and pre-filled syringe filling capacity. The partnership builds upon existing non-sterile manufacturing programs between the two companies.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Cambrex: Cambrex is a leading North American small-molecule API and drug-product CDMO with a similar product portfolio to Halo. Most relevant peer — Halo was previously part of Cambrex (sold to Noramco Group in 2023), making this the closest historical and capability analog.
• Metrics Contract Services: Metrics Contract Services is a US-based solid-dose and semi-solid CDMO focused on pharmaceutical innovators and generics. Directly comparable to Halo's solid dose and semi-solid business, with overlapping customer base and capabilities.
• AMRI (Curia): Curia (formerly AMRI) operates as a contract development and manufacturing organization offering API, drug product, and sterile fill-finish services. Directly comparable as a mid-sized integrated CDMO serving pharma innovators and generics with similar North American footprint.
• Avara Pharmaceutical Services: Avara is a global CDMO providing solid dose, sterile, and API manufacturing services to large pharma. Directly comparable in dosage-form breadth and customer segments, particularly on the commercial manufacturing side.

Broad incumbents

• PCI Pharma Services: PCI Pharma Services is a large integrated CDMO offering drug development, manufacturing, and packaging across multiple dosage forms including sterile injectables. Comparable to Halo's broad service offering but at meaningfully larger scale and global footprint.
• Piramal Pharma Solutions: Piramal Pharma Solutions is a global CDMO offering drug substance and drug product services including sterile fill-finish. Comparable to Halo in dosage-form breadth but with substantially larger global footprint and capacity.
• Recipharm: Recipharm is a European-headquartered CDMO offering solid dose, semi-solid, sterile, and API services. Comparable to Halo in service categories, though operating primarily in Europe with broader geographic reach.
• Aenova Group: Aenova is a European CDMO providing solid dose, semi-solid, liquid, and sterile manufacturing services to pharma and consumer health companies. Comparable in dosage-form breadth to Halo though at larger scale and primarily European geography.
• Siegfried Holding: Siegfried is a global CDMO offering both API and drug product services including sterile fill-finish. Highly comparable — Siegfried acquired Halo's former parent Noramco Group's API assets in May 2026, making it both a peer and a recent counterparty in Halo's restructuring.
• Thermo Fisher Scientific (CDMO Services): Thermo Fisher offers pharma services including drug product development, clinical manufacturing, and commercial supply across solid dose, sterile, and biologics. Overlaps with Halo across multiple service lines but at vastly larger scale and global footprint.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/halo-pharmaceutical-inc-

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Halo Pharmaceutical